Cost of Type 2 Diabetes Management And Associated Complications In Spain

• Published in: Value in health Vol. 20; no. 9; p. A477
• Main Authors: Ramírez de Arellano Serna, A, Rtveladze, K, Planellas, L, Barrull, C, Cel, M
• Format: Journal Article
• Language: English
• Published: Lawrenceville Elsevier Science Ltd 01.10.2017
• Subjects: Autoimmune diseases; Cardiovascular diseases; Cerebral infarction; Complications; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Disease management; Drug therapy; End-stage renal disease; Eye diseases; Feet; Health care expenditures; Health services; Kidney diseases; Literature reviews; Markets; Medical diagnosis; Medical personnel; Medical technology; Medical treatment; Myocardial infarction; Pharmacists; Pharmacology; Physicians; Prices; Tariffs; Type 2 diabetes mellitus; Websites; Spain
• ISSN: 1098-3015; 1524-4733
• DOI: 10.1016/j.jval.2017.08.445

OBJECTIVES: The objective of this study was two-fold. Firstly, to collect up-to-date published cost data for management (pharmacotherapy) and associated complications (cardiovascular, renal, eye disease, diabetic foot and acute events) of type 2 diabetes mellitus in Spain for use in the CORE Diabetes Model (CDM). Secondly, where data was scarce, calculations were carried out to estimate the cost inputs for the CDM- METHODS: A pragmatic literature review for published direct medical costs in English and local languages was performed in four European markets (France, Germany, Italy and Spain) in years 2011-2017. The search was conducted in Embase, MEDLINE, EconLit and NHS EED. Spanish costs were collected from a national or regional public healthcare payer or third party insurer perspective in peer-reviewed journals and on government websites. High impact sources were prioritised such as government tariffs and publications, registry data, physicians' consortium publications or health technology appraisals. Hospital diagnosis-related group (DRG) and ambulatory tariffs were used to update procedures costs, event costs and costs of contacts with healthcare professionals. Where possible, complications costs were taken from the Ministry of Health website (DRG costs) and via eSalud platform. Pharmacotherapy costs were estimated using published prices from the Official College of Pharmacists in Spain. All costs were inflated to 2017 prices, using the Spanish consumer price index. RESULTS: After duplicates were removed there were 1,489 records from four European markets that included 302 abstracts from Spain. 27 articles met the eligibility criteria. The highest cost was for end-stage renal disease ranging between C6,830 and €41,646 followed by diabetic foot (€9,509), myocardial infarction (€6,586) and non-fatal stroke (€6,544). Other cardiovascular, renal and eye disease cost are also identified. Costs are annual. CONCLUSIONS: This study provides the most up-to-date direct medical costs for type 2 diabetes complications and management for use in the Spanish setting.